Cargando…

Responses of patients with cancer to mRNA vaccines depend on the time interval between vaccination and last treatment

BACKGROUND: Personalized mRNA vaccines are promising new therapeutic options for patients with cancer. Because mRNA vaccines are not yet approved for first-line therapy, the vaccines are presently applied to individuals that received prior therapies that can have immunocompromising effects. There is...

Descripción completa

Detalles Bibliográficos
Autores principales: Donhauser, Lara Victoria, Veloso de Oliveira, Julia, Schick, Cordula, Manlik, Wenzel, Styblova, Sabrina, Lutzenberger, Sarah, Aigner, Michael, Philipp, Patrick, Robert, Sebastian, Gandorfer, Beate, Hempel, Dirk, Hempel, Louisa, Zehn, Dietmar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10510941/
https://www.ncbi.nlm.nih.gov/pubmed/37730271
http://dx.doi.org/10.1136/jitc-2023-007387
_version_ 1785108047313502208
author Donhauser, Lara Victoria
Veloso de Oliveira, Julia
Schick, Cordula
Manlik, Wenzel
Styblova, Sabrina
Lutzenberger, Sarah
Aigner, Michael
Philipp, Patrick
Robert, Sebastian
Gandorfer, Beate
Hempel, Dirk
Hempel, Louisa
Zehn, Dietmar
author_facet Donhauser, Lara Victoria
Veloso de Oliveira, Julia
Schick, Cordula
Manlik, Wenzel
Styblova, Sabrina
Lutzenberger, Sarah
Aigner, Michael
Philipp, Patrick
Robert, Sebastian
Gandorfer, Beate
Hempel, Dirk
Hempel, Louisa
Zehn, Dietmar
author_sort Donhauser, Lara Victoria
collection PubMed
description BACKGROUND: Personalized mRNA vaccines are promising new therapeutic options for patients with cancer. Because mRNA vaccines are not yet approved for first-line therapy, the vaccines are presently applied to individuals that received prior therapies that can have immunocompromising effects. There is a need to address how prior treatments impact mRNA vaccine outcomes. METHOD: Therefore, we analyzed the response to BioNTech/Pfizer’s anti-SARS-CoV-2 mRNA vaccine in 237 oncology outpatients, which cover a broad spectrum of hematologic malignancies and solid tumors and a variety of treatments. Patients were stratified by the time interval between the last treatment and first vaccination and by the presence or absence of florid tumors and IgG titers and T cell responses were analyzed 14 days after the second vaccination. RESULTS: Regardless of the last treatment time point, our data indicate that vaccination responses in patients with checkpoint inhibition were comparable to healthy controls. In contrast, patients after chemotherapy or cortisone therapy did not develop an immune response until 6 months after the last systemic therapy and patients after Cht-immune checkpoint inhibitor and tyrosine kinase inhibitor therapy only after 12 months. CONCLUSION: Accordingly, our data support that timing of mRNA-based therapy is critical and we suggest that at least a 6-months or 12-months waiting interval should be observed before mRNA vaccination in systemically treated patients.
format Online
Article
Text
id pubmed-10510941
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-105109412023-09-21 Responses of patients with cancer to mRNA vaccines depend on the time interval between vaccination and last treatment Donhauser, Lara Victoria Veloso de Oliveira, Julia Schick, Cordula Manlik, Wenzel Styblova, Sabrina Lutzenberger, Sarah Aigner, Michael Philipp, Patrick Robert, Sebastian Gandorfer, Beate Hempel, Dirk Hempel, Louisa Zehn, Dietmar J Immunother Cancer Clinical/Translational Cancer Immunotherapy BACKGROUND: Personalized mRNA vaccines are promising new therapeutic options for patients with cancer. Because mRNA vaccines are not yet approved for first-line therapy, the vaccines are presently applied to individuals that received prior therapies that can have immunocompromising effects. There is a need to address how prior treatments impact mRNA vaccine outcomes. METHOD: Therefore, we analyzed the response to BioNTech/Pfizer’s anti-SARS-CoV-2 mRNA vaccine in 237 oncology outpatients, which cover a broad spectrum of hematologic malignancies and solid tumors and a variety of treatments. Patients were stratified by the time interval between the last treatment and first vaccination and by the presence or absence of florid tumors and IgG titers and T cell responses were analyzed 14 days after the second vaccination. RESULTS: Regardless of the last treatment time point, our data indicate that vaccination responses in patients with checkpoint inhibition were comparable to healthy controls. In contrast, patients after chemotherapy or cortisone therapy did not develop an immune response until 6 months after the last systemic therapy and patients after Cht-immune checkpoint inhibitor and tyrosine kinase inhibitor therapy only after 12 months. CONCLUSION: Accordingly, our data support that timing of mRNA-based therapy is critical and we suggest that at least a 6-months or 12-months waiting interval should be observed before mRNA vaccination in systemically treated patients. BMJ Publishing Group 2023-09-19 /pmc/articles/PMC10510941/ /pubmed/37730271 http://dx.doi.org/10.1136/jitc-2023-007387 Text en © Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Clinical/Translational Cancer Immunotherapy
Donhauser, Lara Victoria
Veloso de Oliveira, Julia
Schick, Cordula
Manlik, Wenzel
Styblova, Sabrina
Lutzenberger, Sarah
Aigner, Michael
Philipp, Patrick
Robert, Sebastian
Gandorfer, Beate
Hempel, Dirk
Hempel, Louisa
Zehn, Dietmar
Responses of patients with cancer to mRNA vaccines depend on the time interval between vaccination and last treatment
title Responses of patients with cancer to mRNA vaccines depend on the time interval between vaccination and last treatment
title_full Responses of patients with cancer to mRNA vaccines depend on the time interval between vaccination and last treatment
title_fullStr Responses of patients with cancer to mRNA vaccines depend on the time interval between vaccination and last treatment
title_full_unstemmed Responses of patients with cancer to mRNA vaccines depend on the time interval between vaccination and last treatment
title_short Responses of patients with cancer to mRNA vaccines depend on the time interval between vaccination and last treatment
title_sort responses of patients with cancer to mrna vaccines depend on the time interval between vaccination and last treatment
topic Clinical/Translational Cancer Immunotherapy
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10510941/
https://www.ncbi.nlm.nih.gov/pubmed/37730271
http://dx.doi.org/10.1136/jitc-2023-007387
work_keys_str_mv AT donhauserlaravictoria responsesofpatientswithcancertomrnavaccinesdependonthetimeintervalbetweenvaccinationandlasttreatment
AT velosodeoliveirajulia responsesofpatientswithcancertomrnavaccinesdependonthetimeintervalbetweenvaccinationandlasttreatment
AT schickcordula responsesofpatientswithcancertomrnavaccinesdependonthetimeintervalbetweenvaccinationandlasttreatment
AT manlikwenzel responsesofpatientswithcancertomrnavaccinesdependonthetimeintervalbetweenvaccinationandlasttreatment
AT styblovasabrina responsesofpatientswithcancertomrnavaccinesdependonthetimeintervalbetweenvaccinationandlasttreatment
AT lutzenbergersarah responsesofpatientswithcancertomrnavaccinesdependonthetimeintervalbetweenvaccinationandlasttreatment
AT aignermichael responsesofpatientswithcancertomrnavaccinesdependonthetimeintervalbetweenvaccinationandlasttreatment
AT philipppatrick responsesofpatientswithcancertomrnavaccinesdependonthetimeintervalbetweenvaccinationandlasttreatment
AT robertsebastian responsesofpatientswithcancertomrnavaccinesdependonthetimeintervalbetweenvaccinationandlasttreatment
AT gandorferbeate responsesofpatientswithcancertomrnavaccinesdependonthetimeintervalbetweenvaccinationandlasttreatment
AT hempeldirk responsesofpatientswithcancertomrnavaccinesdependonthetimeintervalbetweenvaccinationandlasttreatment
AT hempellouisa responsesofpatientswithcancertomrnavaccinesdependonthetimeintervalbetweenvaccinationandlasttreatment
AT zehndietmar responsesofpatientswithcancertomrnavaccinesdependonthetimeintervalbetweenvaccinationandlasttreatment